Abstract
The current diagnostic threshold for diabetes mellitus is imposed on a continuous distribution of blood glucose measurement. A more clinical approach estimates a threshold above which the rate of diabetes-specific complications rises steeply. However, the diagnostic threshold for diabetes is essentially established on the risk of microvascular and not cardiovascular complications. Indeed, while there appears to be a continuous relationship between blood glucose, cardiovascular risk and overall mortality, this association extends into the sub-diabetic range, with no threshold identified. In this regard, the assumption that the diagnosis of diabetes can effectively identify patients at elevated risk of cardiovascular morbidity and mortality is potentially flawed, and questions the utility of diabetes status (as a dichotomous variable) for the assessment and management of cardiovascular risk. Indeed, the increased risk of cardiovascular complications may not be related to diabetes status per se but the frequent association of diabetes with a high-risk phenotype, now recognised as the so-called ‘metabolic syndrome’. By implication, cardiovascular disease prevention should not be dominated by a drive for the prevention of diabetes, but this broader clinical syndrome of increased cardiovascular risk.
Keywords: oral glucose tolerance testing, cardiovascular risk, dyslipidaemia, International Diabetes Federation, metabolic syndrome
Current Pharmaceutical Design
Title: From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept
Volume: 13 Issue: 25
Author(s): Hoong Sern Lim and Gregory Y.H. Lip
Affiliation:
Keywords: oral glucose tolerance testing, cardiovascular risk, dyslipidaemia, International Diabetes Federation, metabolic syndrome
Abstract: The current diagnostic threshold for diabetes mellitus is imposed on a continuous distribution of blood glucose measurement. A more clinical approach estimates a threshold above which the rate of diabetes-specific complications rises steeply. However, the diagnostic threshold for diabetes is essentially established on the risk of microvascular and not cardiovascular complications. Indeed, while there appears to be a continuous relationship between blood glucose, cardiovascular risk and overall mortality, this association extends into the sub-diabetic range, with no threshold identified. In this regard, the assumption that the diagnosis of diabetes can effectively identify patients at elevated risk of cardiovascular morbidity and mortality is potentially flawed, and questions the utility of diabetes status (as a dichotomous variable) for the assessment and management of cardiovascular risk. Indeed, the increased risk of cardiovascular complications may not be related to diabetes status per se but the frequent association of diabetes with a high-risk phenotype, now recognised as the so-called ‘metabolic syndrome’. By implication, cardiovascular disease prevention should not be dominated by a drive for the prevention of diabetes, but this broader clinical syndrome of increased cardiovascular risk.
Export Options
About this article
Cite this article as:
Lim Sern Hoong and Lip Y.H. Gregory, From Diabetes to Metabolic Syndrome: A View Point on An Evolving Concept, Current Pharmaceutical Design 2007; 13 (25) . https://dx.doi.org/10.2174/138161207781663028
DOI https://dx.doi.org/10.2174/138161207781663028 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Endocrine Disruptor Bisphenol A (BPA) Exerts a Wide Range of Effects in Carcinogenesis and Response to Therapy
Current Molecular Pharmacology N6-methyladenine RNA Modification (m<sup>6</sup>A): An Emerging Regulator of Metabolic Diseases
Current Drug Targets The Wnt/β-catenin Signalling Pathway Inhibitor Sclerostin is a Biomarker for Early Atherosclerosis in Obesity
Current Neurovascular Research Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old
Current Alzheimer Research Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review
Mini-Reviews in Medicinal Chemistry Complement 3 Receptor Expression in Individuals with Type 2 Diabetes
Recent Patents on Anti-Infective Drug Discovery Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Disparities in Cardiovascular Disease Risk in the United States
Current Cardiology Reviews Editorial from Editor-in-Chief: Hypoglossal Nerve Stimulation: An Emerging and Futuristic Therapy for Obstructive Sleep Apnea
Current Respiratory Medicine Reviews Targeting Chemokine (C-X-C motif) Receptor 3 in Thyroid Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Pancreatic Cancer in Obesity: Epidemiology, Clinical Observations, and Basic Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Insights into the Conformational Ensemble of Human Islet Amyloid Polypeptide from Molecular Simulations
Current Pharmaceutical Design Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?
Current Medicinal Chemistry Lifestyle Factors and MicroRNAs: A New Paradigm in Cancer Chemoprevention
MicroRNA α7 Nicotinic Receptor Agonists as Potential Therapeutic Drugs for Schizophrenia
Current Medicinal Chemistry - Central Nervous System Agents